SUBSCRIBE
SUBSCRIBE
Greg Slabodkin

Greg Slabodkin

Greg is a seasoned editor/writer who has covered the healthcare, life sciences and medical device industries for several tech trade publications. He is the recipient of a Post-Newsweek Business Information Editorial Excellence Award for his news reporting and a Gold Award for Best Case Study from the American Society of Healthcare Publication Editors. In addition, Greg is a Healthcare Fellow from the Society for Advancing Business Editing and Writing. He is an avid Buffalo Bills football fan, likes to kayak and plays guitar.

Pictured: U.S. Capitol Building, Washington DC
Policy
Stakeholders Hope Bill Will Create IRA Drug Negotiation Parity Between Biologics and Small Molecules
Congressional legislation seeks to “equalize” the negotiating period between biologics and small molecules under the Inflation Reduction Act’s Drug Price Negotiation Program.
February 28, 2024
 · 
5 min read
 · 
Greg Slabodkin
AbbVie's office in South San Francisco, California
Business
AbbVie’s Humira Is a Textbook Case for Drugmakers Navigating Patent Cliff
Thanks to the success of outgoing CEO Richard Gonzalez, biopharma executives will be studying for years to come how AbbVie navigated the decline of blockbuster Humira.
February 23, 2024
 · 
3 min read
 · 
Greg Slabodkin
Drug Delivery
Iovance wins with Amtagvi and the ADC train chugs on
This week Lori, Greg and Tyler discuss the ⁠Accelerated Approval of Amtagvi⁠, the first one-time cell therapy for solid tumors and the first TIL therapy; the ⁠FTC and HHS probe⁠ into generic drug shortages and some recent ADC-focused raises from ⁠ProfoundBio⁠ and ⁠Firefly Bio⁠.
February 20, 2024
 · 
1 min read
 · 
Lori Ellis
Pictured: Wall sign of the Novo Nordisk Foundation and Novo Holdings in Denmark
Business
Novo Rides to Catalent’s Rescue in $16.5B Deal. Now What?
Novo Nordisk seems to believe it can do a better job managing troubled Catalent than the contract manufacturer. However, the Danish drugmaker has its work cut out for it.
February 16, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: Photo illustration of hundred dollar bil
Business
COVID-19 Cliff and Skyrocketing GLP-1 Drug Sales Highlight Q4 2023 Earnings
Biopharma’s latest earnings season was, in a word, predictable. Companies are consistently beating Wall Street earnings and revenue estimates as they set low expectations for investors.
February 9, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: Concept of USA pharmaceutical market and
Drug Delivery
Drug Pricing Reforms Front and Center as 2024 Election Ramps Up
The U.S. Department of Health and Human Services on Thursday released new data showing that Americans pay three times more for prescription drugs than other developed countries and nearly 10 times more for insulin.
February 2, 2024
 · 
3 min read
 · 
Greg Slabodkin
Drug Development
Keep calm and CAR-T on?
Lori, Greg and Tyler discuss last week’s ⁠call for a class-wide box warning⁠ on all commercial CAR T therapies, while investigations are ongoing into ⁠cases of secondary malignancies⁠. How do we approach this ⁠balancing act⁠ of treatment and side effects?
January 31, 2024
 · 
1 min read
 · 
Lori Ellis
Pictured: Illustration of a pile of question marks
Drug Development
CAR T Cell Conundrum: When Patients Develop New Cancers After Treatment
While the FDA continues to investigate reported cases of T cell malignancies in patients who received CAR-T therapies, the cause of the secondary cancers remains unclear.
January 26, 2024
 · 
3 min read
 · 
Greg Slabodkin
Deals
Grab an umbrella, it’s raining ⁠IPOs⁠!
This week, Lori, Greg and Tyler discuss the first ⁠surge of IPO activity⁠ this year plus gene therapy pricing,
January 23, 2024
 · 
1 min read
 · 
Lori Ellis
Pictured: Wall Street street sign in front of Amer
Biotech Bay
2024 Brings Surprising Early Surge of Biotech IPOs
Whether this year’s crop of IPOs—Alto Neuroscience, ArriVent Biopharma, CG Oncology, Kyverna Therapeutics and Metagenomi—will trade below their offering prices remains to be seen.
January 19, 2024
 · 
3 min read
 · 
Greg Slabodkin
Drug Development
Optimistic, but for how long? Our big takeaways from #JPM2024
The team comes together to discuss the dominant themes of what was an incredibly busy week of events in San Francisco during JPM 2024.
January 17, 2024
 · 
1 min read
 · 
Lori Ellis
Pictured: Photo of a trolley in San Francisco/Tyle
JPM2024 Offers Cautious Optimism About Year Ahead. Will It Last?
There seems to be decidedly positive sentiment regarding biopharma in 2024—perhaps a harbinger of things to come this year coming off a topsy-turvy 2023.
January 12, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: Aerial view of the San Francisco skyline
Policy
JPM2024: IRA Favors Biologics Over Small Molecule Drugs and Hurts Innovation, Industry Analysts Say
Biologics have a major advantage over small molecule drugs under the Inflation Reduction Act’s provisions, according to stakeholders attending this week’s J.P. Morgan conference.
January 11, 2024
 · 
3 min read
 · 
Greg Slabodkin
Deals
Listen: JPM2024 Day 3 Highlights
The BioSpace team is recording from San Francisco as they bring you the the latest highlights from Day 3 at JPM2024.
January 10, 2024
 · 
1 min read
 · 
Lori Ellis
A doctor points to a smartphone app while a patien
JPM2024: Big Tech Poised to Disrupt Biopharma with AI-Based Drug Discovery
On Sunday, ahead of the J.P. Morgan Healthcare Conference, Alphabet’s artificial intelligence startup Isomorphic Labs secured its first pharma partnerships with Eli Lilly and Novartis worth nearly $3 billion.
January 10, 2024
 · 
3 min read
 · 
Greg Slabodkin
Load More